The European Journal of Public Health, Vol. 28, No. 1, 145–149
The Author 2017. Published by Oxford University Press on behalf of the European Public Health Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:...//creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
doi:10.1093/eurpub/ckx122 Advance Access published on 31 August 2017
more
Kan M et al. Journal of the International AIDS Society 2018, 21(S5):e25139 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25139/full | https://doi.org/10.1002/jia2.25139
F1000Research 2019, 8:323 Last updated: 17 MAY 2019
PLOS ONE | https://doi.org/10.1371/journal.pone.0185526 September 28, 2017
Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, IHMT, Universidade Nova de Lisboa, UNL, Lisboa, Portugal
International Journal of Infectious Diseases 46 (2016) 56–60
braz j infect dis. 2014;18(5):491–495
http://dx.doi.org/10.1016/j.bjid.2014.02.004
1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Child Survival Working Group
Accessed: 18.10.2019
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5 http://www.biomedcentral.com/1471-2334/14/S1/S5
PLOS ONE | www.plosone.org 1
December 2013 | Volume 8 | Issue 12 | e82027
Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
For children orphaned or made vulnerable by HIV (OVC)
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
PLOS ONE | www.plosone.org 1
January 2014 | Volume 9 | Issue 1 | e86616